Skip To Main Content
Ebenezer A. Kio on Muck Rack

Ebenezer A. Kio

As seen in: Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ebenezer A.

Contact Ebenezer A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study

|
By Jeffrey M. Clarke, Jyoti D Patel Verified, Francisco Robert, Ebenezer A. Kio
| Lung Cancer Verified
Highlights: • Veliparib, a PARP inhibitor, enhances cytotoxicity induced by chemotherapy (CT) • Nivolumab, a PD-1 inhibitor, plus CT demonstrated efficacy for NSCLC treatment. • This is a phase 1 trial of veliparib + nivolumab + CT in unresectable stage III NSCLC. • This quadruple therapy was tolerated, and no drug-drug interaction was observed. • This combination suggests promising antitumor activity.
Open in Who Shared Issue with article?
See all 1 articles